Cann American Corp.
Cann American Corp.
Your view on CNNA
Overview
What the company does, where it operates, and who runs it.
About Cann American Corp.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jason R. Tucker
- Headquarters
- 320 Santana Drive, Cloverdale, CA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jason R. Tucker
- Headquarters
- 320 Santana Drive, Cloverdale, CA, US
Cann American Corp., a development stage company, focuses on the development of Cannabis sativa strains for pets in various European Union countries. The company was formerly known as Canamed4Pets, Inc. and changed its name to Cann American Corp. in December 2019. Cann American Corp. was founded in 2004 and is based in Cloverdale, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cann American Corp., and the rating behind it. CNNA last traded at $0.0015, 0.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cann American Corp.. Starting points for Cann American Corp.: P/E 0.5, EPS $0.01, beta -0.85 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cann American Corp.. Cann American Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cann American Corp.. Trailing twelve-month EPS for Cann American Corp. stands at $0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cann American Corp.. Cann American Corp. has reported as a listed company since 2011. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cann American Corp. valued side by side against its closest peers. Cann American Corp. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cann American Corp., and how their positions are changing. At a $1.1M market value, institutional positions materially move Cann American Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cann American Corp. executives and directors. Shares of Cann American Corp. have traded between $0.0001 and $0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cann American Corp.. Cann American Corp. is a $1.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cann American Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cann American Corp.. Coverage tracks Cann American Corp. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.